Trials / Recruiting
RecruitingNCT05217940
Screening Women With Prior HPV for Anal Neoplasia
The Effectiveness of Screening Women With Lower Genital Tract Neoplasia or Cancers for Anal Cancer Precursors
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Icahn School of Medicine at Mount Sinai · Academic / Other
- Sex
- Female
- Age
- 35 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this single arm trial is to prospectively evaluate screening methods for anal cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias and cancers.
Detailed description
This single arm trial will enroll 300 HIV uninfected women with a history of genital neoplasia (ie., cervical intraepithelial neoplasia grade 2-3, vaginal intraepithelial neoplasia grade 2-3 or vulvar intraepithelial neoplasia grade 2-3) or early stage cervical or vulvar cancer to evaluate the test characteristics of anal cancer screening tests (cytology, HPV testing and high resolution anoscopy) and determine the prevalence and incidence of anal high-grade squamous intraepithelial lesions in this population. Participants will undergo evaluation at baseline and then at 12 and 24 months. The investigators will also measure the acceptability of anal cancer screening in this previously unstudied group. The trial is expected to run from 2021-2027.
Conditions
- HPV-related Lower Genital Tract Neoplasias
- HPV-related Anal Neoplasias
- Early Stage Lower Genital Tract Cancers
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Diagnostic tests for anal cancer screening | The initial screening interventions will include the collection of (1) anal cytology; (2) self-collected HPV testing specimens (by subjects); (3) a clinician collected HPV specimen. A digital rectal exam will also be done on all patients. |
Timeline
- Start date
- 2022-03-02
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
- First posted
- 2022-02-01
- Last updated
- 2025-08-22
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05217940. Inclusion in this directory is not an endorsement.